NDASUBCUTANEOUSSOLUTION
Approved
Oct 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VYALEV is a subcutaneous solution containing foscarbidopa and foslevodopa, approved by the FDA in October 2024. It is a prodrug formulation designed for Parkinson's disease management via continuous subcutaneous infusion. The mechanism leverages levodopa delivery with carbidopa as a decarboxylase inhibitor to optimize dopaminergic therapy.
Growth13.8 years to LOE
Recently launched product in growth phase with potential to expand market share in Parkinson's disease; commercial team build-out and field force expansion likely underway.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VYALEV represents a newly launched product with strong patent protection and significant growth potential in the Parkinson's disease market. Joining the team during this growth phase offers visibility, autonomy in building market presence, and long-term career stability through 2040.
Brand ManagerField Sales Representative
Worked on VYALEV at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.